Emerging Penny Stocks To Watch In October 2024

In This Article:

As global markets experience varied movements, with the S&P 500 advancing and small-cap indices outperforming, investors are keenly observing opportunities across different market segments. Despite the vintage feel of the term "penny stocks," these investments remain relevant as they often represent smaller or newer companies with potential for significant growth. When backed by strong financials, penny stocks can offer a unique chance to uncover hidden value at lower price points, making them an intriguing option for those seeking growth in today's market landscape.

Top 10 Penny Stocks

Name

Share Price

Market Cap

Financial Health Rating

BP Plastics Holding Bhd (KLSE:BPPLAS)

MYR1.21

MYR340.59M

★★★★★★

DXN Holdings Bhd (KLSE:DXN)

MYR0.585

MYR2.93B

★★★★★★

Lever Style (SEHK:1346)

HK$0.77

HK$488.79M

★★★★★★

Rexit Berhad (KLSE:REXIT)

MYR0.735

MYR129.91M

★★★★★★

Zhejiang Giuseppe Garment (SZSE:002687)

CN¥4.39

CN¥2.11B

★★★★★★

Tristel (AIM:TSTL)

£4.00

£183.45M

★★★★★★

Hil Industries Berhad (KLSE:HIL)

MYR0.92

MYR307.05M

★★★★★★

FRP Advisory Group (AIM:FRP)

£1.235

£307.76M

★★★★★★

Next 15 Group (AIM:NFG)

£4.065

£405.78M

★★★★☆☆

Embark Early Education (ASX:EVO)

A$0.80

A$127.64M

★★★★☆☆

Click here to see the full list of 5,800 stocks from our Penny Stocks screener.

Let's take a closer look at a couple of our picks from the screened companies.

LifeTech Scientific

Simply Wall St Financial Health Rating: ★★★★★★

Overview: LifeTech Scientific Corporation is an investment holding company that develops, manufactures, and trades interventional medical devices for cardiovascular and peripheral vascular diseases globally, with a market cap of HK$6.20 billion.

Operations: The company generates its revenue from three main segments: Structural Heart Diseases Business (CN¥523.01 million), Peripheral Vascular Diseases Business (CN¥725.13 million), and Cardiac Pacing and Electrophysiology Business (CN¥32.36 million).

Market Cap: HK$6.2B

LifeTech Scientific Corporation's financial health appears robust, with short-term assets (CN¥2.2 billion) surpassing both its short-term liabilities (CN¥826.5 million) and long-term liabilities (CN¥602.8 million). The company's cash flow comfortably covers its debt, and it holds more cash than total debt, indicating strong liquidity. Despite a reduction in profit margins from 28% to 19.4%, LifeTech's earnings are forecasted to grow by 29.5% annually, suggesting potential future growth. However, recent performance showed negative earnings growth of -24.8%, impacted by a significant one-off loss of CN¥139.3 million over the past year ending June 2024.